Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | HMGCR | P04035 | 5/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932579 | 1.00 | PTPN1 (0.38) | PTPN1HMGCRTBXAS1PPARDGABRR1 | |
| SCHEMBL4238610 | 1.00 | PTPN1 (0.38) | PTPN1HMGCRTBXAS1PPARDGABRR1 | |
| SCHEMBL14471722 | 0.87 | TSHR (0.37) | PTPN1GABRR1GABRR2BLMGABRR3 | |
| SCHEMBL14471551 | 0.87 | TSHR (0.37) | PTPN1GABRR1GABRR2BLMGABRR3 | |
| SCHEMBL14471549 | 0.87 | TSHR (0.37) | PTPN1GABRR1GABRR2BLMGABRR3 | |
| SCHEMBL4245970 | 0.83 | PTPN1 (0.40) | PTPN1TBXAS1PPARDBLMLMNA | |
| SCHEMBL16287670 | 0.81 | CYP1A2 (0.47) | PTPN1TBXAS1GABRR1GABRR2BLM | |
| SCHEMBL16287668 | 0.81 | CYP1A2 (0.47) | PTPN1TBXAS1GABRR1GABRR2BLM | |
| SCHEMBL4234744 | 0.81 | HMGCR (0.42) | PTPN1HMGCRTBXAS1PPARDPTPN7 | |
| SCHEMBL4238508 | 0.81 | FAAH (0.37) | PTPN1TBXAS1GABRR1GABRR2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041370-A1 | 1H-PYRROLE-2,4-DICARBONYL-DERIVATIVES AND THEIR USE AS FLAVORING AGENTS | IMAX Discovery GmbH (DE) | 2016-07-13 | — | — | EP | claimed |
| WO-2015014609-A1 | 1H-PYRROLE-2,4-DICARBONYL-DERIVATIVES AND THEIR USE AS FLAVORING AGENTS | IMAX DISCOVERY GMBH (DE) | 2015-02-05 | — | — | WO | claimed |
| WO-2015014607-A1 | IMIDAZO[1,2-A]PYRIDINE-YLMETHYL-DERIVATIVES AND THEIR USE AS FLAVORING AGENTS | IMAX DISCOVERY GMBH (DE) | 2015-02-05 | — | — | WO | claimed |
| EP-2832233-A1 | 1H-pyrrole-2,4-dicarbonyl-derivatives and their use as flavoring agents | IMAX Discovery GmbH (DE) | 2015-02-04 | — | — | EP | claimed |
| EP-2832234-A1 | Imidazo[1,2-a]pyridine-ylmethyl-derivatives and their use as flavoring agents | IMAX Discovery GmbH (DE) | 2015-02-04 | — | — | EP | claimed |
| WO-2013135511-A1 | N-(2,4-DIMETHYLPENTAN-3-YL)-METHYLBENZAMIDES AND THEIR USE AS FLAVORING AGENTS | IMAX DISCOVERY GMBH (DE) | 2013-09-19 | — | — | WO | claimed |
| EP-3041370-A1 | 1H-PYRROLE-2,4-DICARBONYL-DERIVATIVES AND THEIR USE AS FLAVORING AGENTS | IMAX Discovery GmbH (DE) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015014607-A1 | IMIDAZO[1,2-A]PYRIDINE-YLMETHYL-DERIVATIVES AND THEIR USE AS FLAVORING AGENTS | IMAX DISCOVERY GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015014609-A1 | 1H-PYRROLE-2,4-DICARBONYL-DERIVATIVES AND THEIR USE AS FLAVORING AGENTS | IMAX DISCOVERY GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| EP-2832233-A1 | 1H-pyrrole-2,4-dicarbonyl-derivatives and their use as flavoring agents | IMAX Discovery GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| EP-2832234-A1 | Imidazo[1,2-a]pyridine-ylmethyl-derivatives and their use as flavoring agents | IMAX Discovery GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013135511-A1 | N-(2,4-DIMETHYLPENTAN-3-YL)-METHYLBENZAMIDES AND THEIR USE AS FLAVORING AGENTS | IMAX DISCOVERY GMBH (DE) | 2013-09-19 | — | — | WO | disclosed |
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2009-02-26 | — | — | US | disclosed |
| US-20080160116-A1 | Compositions and Methods Comprising Zingiber Species | HERBALSCIENCE SINGAPORE PTE. LTD (SG) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | LIPE, PNLIP, FAAH2 | PTPN1 2880/4885HMGCR 1770/4885TBXAS1 1123/4885 |
| US-20080160116-A1 | Compositions and Methods Comprising Zingiber Species | AGL, SQLE, RBPJ | PTPN1 3368/4885HMGCR 43/4885TBXAS1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.